Summary
TYK2 inhibitors are emerging as a major class of oral immunology therapies, aiming to combine biologic-level efficacy with the convenience of a pill and fewer safety concerns than broader JAK inhibitors.
Bristol Myers Squibb’s SOTYKTU remains the first approved TYK2 inhibitor and expanded its position in 2026 with FDA approval for active psoriatic arthritis.
Takeda’s zasocitinib has significantly intensified competition after outperforming SOTYKTU in a head-to-head Phase 3 psoriasis trial, with more than 35% of patients achieving complete skin clearance at Week 16.
Other promising candidates, including Alumis and Kaken Pharmaceutical’s Envudeuciti...
